Read by QxMD icon Read

Clinical Lung Cancer

Ashwini Arunachalam, Haojie Li, Marisa A Bittoni, Ramon Camacho, Xiting Cao, Yichen Zhong, Gregory M Lubiniecki, David P Carbone
INTRODUCTION: Real-world data on current treatment practices for non-small-cell lung cancer (NSCLC) are needed to understand the place in therapy and potential economic impact of newer therapies. PATIENTS AND METHODS: This retrospective cohort study identified patients ≥ 65 years old in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database with first-time diagnosis of stage IIIB/IV NSCLC from 2007-2011 who received second-line therapy after first-line platinum-based chemotherapy from 2007 through mid-2013...
June 6, 2018: Clinical Lung Cancer
Govind Raghavan, Narek Shaverdian, Shawna Chan, Fang-I Chu, Percy Lee
INTRODUCTION: Frailty of surgical patients has been associated with worse outcomes. There is limited literature discussing frailty in patients with lung cancer treated with stereotactic body radiotherapy (SBRT). This study assesses the relationship between frailty and overall survival (OS), tumor control, and toxicity in patients with early-stage non-small-cell lung cancer (NSCLC) treated with SBRT. PATIENTS AND METHODS: A retrospective review of patients with early-stage NSCLC treated with SBRT at a single institution between February 2009 and September 2014 was performed...
June 6, 2018: Clinical Lung Cancer
Adrian Lee, Viive M Howell, Malinda Itchins, Helen R Wheeler, Nick Pavlakis
No abstract text is available yet for this article.
June 5, 2018: Clinical Lung Cancer
Christopher T Su, Amit Bhargava, Chirag D Shah, Balazs Halmos, Rasim A Gucalp, Stuart H Packer, Nitin Ohri, Linda B Haramati, Roman Perez-Soler, Haiying Cheng
BACKGROUND: The landmark National Lung Screening Trial demonstrated significant reduction in lung cancer-related mortality. However, European lung cancer screening (LCS) trials have not confirmed such benefit. We examined LCS patterns and determined the impact of LCS-led diagnosis on the mortality of newly diagnosed patients with lung cancer in an underserved community. PATIENTS AND METHODS: Medical records of patients diagnosed with primary lung cancer in 2013 through 2016 (n = 855) were reviewed for primary care provider (PCP) status and LCS eligibility and completion, determined using United States Preventative Services Task Force guidelines...
June 5, 2018: Clinical Lung Cancer
Davide Paolini, Marcello Tiseo, Federica Demma, Gianluca Furneri, Matteo Dionisi, Marlene Akkermans, Antonio Marchetti
BACKGROUND: To ensure identification of anaplastic lymphoma kinase-positive (ALK+ ) patients, the Italian Drug Agency suggested a testing algorithm based on the use of fluorescence in situ hybridization (FISH) and/or immunohistochemistry. The aim was to evaluate the clinical and economic effects of adopting an immunohistochemical test (Ventana ALK D5F3) as an option for detecting ALK protein expression in advanced non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: A budget impact model was developed by adopting the Italian National Health Service (NHS) perspective and a 5-year period to compare 2 scenarios: the current use of D5F3 (28%; current scenario) and increased use of D5F3 (60%; alternative scenario)...
May 31, 2018: Clinical Lung Cancer
Alexander Vittorio, Rajiv Sharma, Dylan Siejka, Keshav Bhattarai, Ashutosh Hardikar
No abstract text is available yet for this article.
May 26, 2018: Clinical Lung Cancer
Hayato Kawachi, Daichi Fujimoto, Takeshi Morimoto, Munehiro Ito, Shunsuke Teraoka, Yuki Sato, Kazuma Nagata, Atsushi Nakagawa, Kojiro Otsuka, Keisuke Tomii
BACKGROUND: Most patients with non-small-cell lung cancer (NSCLC) are ineligible for clinical trials. However, few studies have reported on the profiles and treatment outcomes for these patients. Therefore, we investigated the characteristics, outcomes, and survival of patients with advanced NSCLC who were ineligible for clinical trials. MATERIALS AND METHODS: We analyzed the data from a retrospective cohort of 786 consecutive patients with a diagnosis of advanced NSCLC...
May 26, 2018: Clinical Lung Cancer
Yoshihito Kogure, Hideo Saka, Yuichi Takiguchi, Shinji Atagi, Takayasu Kurata, Noriyuki Ebi, Akira Inoue, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Akiko Kada, Takeharu Yamanaka, Masahiko Ando, Nobuyuki Yamamoto, Akihiko Gemma, Yukito Ichinose
BACKGROUND: Treatment with carboplatin (CBDCA) with weekly paclitaxel (PTX) has shown survival benefits compared with vinorelbine or gemcitabine in elderly patients with non-small-cell carcinoma (NSCLC). Docetaxel (DOC), however, remains a standard treatment in NSCLC. The 130-nm albumin-bound formulation of PTX (nab-PTX) has shown activity in NSCLC. Treatment with CBDCA with weekly nab-PTX showed significantly higher efficacy than CBDCA with PTX in patients with squamous histology and significantly increased overall survival (OS) in patients aged 70 years and older...
May 19, 2018: Clinical Lung Cancer
Srinivas Raman, Jean-Pierre Bissonnette, Andrew Warner, Lisa Le, Scott Bratman, Natasha Leighl, Andrea Bezjak, David Palma, Devin Schellenberg, Alexander Sun
We explain the rationale for metabolically adaptive radiation dose escalation in stage III non-small-cell lung cancer and describe the design of a Canadian phase II randomized trial investigating this approach. In the trial, patients are randomized to either conventional chemoradiation treatment (60 Gy in 30 fractions) or metabolically adaptive chemoradiation, where fluorodeoxyglucose-avid tumor sub-volumes receive an integrated boost dose to a maximum of 85 Gy in 30 fractions. The trial sample size is 78 patients, and the target population is patients with newly diagnosed, inoperable stage III non-small-cell lung cancer treated with radical intent chemoradiation...
May 16, 2018: Clinical Lung Cancer
Nuria Rodríguez de Dios, Felipe Couñago, José Luis López, Patricia Calvo, Mauricio Murcia, Mikel Rico, Carmen Vallejo, Javier Luna, Itziar Trueba, Cristina Cigarral, Nuria Farre, Rosa Maria Manero, Xavier Durán, Pilar Samper
BACKGROUND: Prophylactic cranial irradiation (PCI) is part of the usual treatment in most patients with small-cell lung cancer (SCLC) and response after treatment of the primary tumor. Clinical evidence suggests that radiation dose received by the hippocampus during whole brain radiotherapy might play a role in radiation-induced neurocognitive decline. PATIENTS AND METHODS: This study is a multicenter phase III trial (NCT02397733) randomizing SCLC patients after informed consent, to receive standard PCI treatment or PCI with hippocampus avoidance (PCI-HA) by using intensity modulated radiation therapy or volumetric modulated arc therapy...
May 10, 2018: Clinical Lung Cancer
Masafumi Saiki, Satoru Kitazono, Takahiro Yoshizawa, Yosuke Dotsu, Ryo Ariyasu, Junji Koyama, Tomoaki Sonoda, Ken Uchibori, Shingo Nishikawa, Noriko Yanagitani, Atsushi Horiike, Fumiyoshi Ohyanagi, Katsunori Oikado, Hironori Ninomiya, Kengo Takeuchi, Yuichi Ishikawa, Makoto Nishio
BACKGROUND: Rearranged during transfection (RET)-rearranged non-small-cell lung cancer (NSCLC) is relatively rare and the clinical and computed tomography (CT) image characteristics of patients with an advanced disease stage have not been well documented. PATIENTS AND METHODS: We identified patients with advanced-stage RET-rearranged NSCLC treated in the Cancer Institute Hospital, Japanese Foundation for Cancer Research, and analyzed the clinical and CT imaging characteristics...
May 10, 2018: Clinical Lung Cancer
Nobukazu Fujimoto, Keisuke Aoe, Toshiyuki Kozuki, Isao Oze, Katsuya Kato, Takumi Kishimoto, Katsuyuki Hotta
BACKGROUND: The purpose of this study is to assess the efficacy and safety of combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (MPM). PATIENTS AND METHODS: Patients with untreated, advanced, or metastatic MPM who meet the inclusion and exclusion criteria will be included. A total of 18 patients will be enrolled from 4 Japanese institutions within 1 year. Combination chemotherapy with cisplatin (75 mg/m2 ), pemetrexed (500 mg/m2 ), and nivolumab (360 mg/person) is administered every 3 weeks for a total of 4 to 6 cycles...
May 9, 2018: Clinical Lung Cancer
Alona Zer, Mike R Sung, Preet Walia, Leila Khoja, Manjula Maganti, Catherine Labbe, Frances A Shepherd, Penelope A Bradbury, Ronald Feld, Geoffrey Liu, Melissa Iazzi, Dianne Zawisza, Nazanin Nouriany, Natasha B Leighl
INTRODUCTION: Programmed death-1 (PD-1) axis inhibitors have become standard therapy in advanced non-small-cell lung cancer (NSCLC). Response might be delayed and pseudo-progression occasionally occurs in patients who eventually benefit from treatment. Additional markers beyond programmed death ligand 1 (PD-L1) expression are needed to assist in patient selection, response evaluation, and treatment decisions. MATERIALS AND METHODS: The relationship between prospectively collected clinical outcomes (response, disease control rate [DCR], treatment duration, overall survival) and hematologic parameters (neutrophil to lymphocyte ratio [NLR], absolute neutrophil count [ANC], and platelet to lymphocyte ratio [PLR]) was explored retrospectively in advanced NSCLC patients treated with PD-1 axis inhibitors at a major cancer center from May 2013 to August 2016...
May 8, 2018: Clinical Lung Cancer
Vera Hirsh, Yin Wan, Fang-Ju Lin, Sandra Margunato-Debay, Teng Jin Ong, Marc Botteman, Corey Langer
BACKGROUND: First-line nab-paclitaxel/carboplatin was associated with a significantly improved overall response rate (primary endpoint) versus paclitaxel/carboplatin in a phase III trial of advanced non-small-cell lung cancer (NSCLC). We report the results of an analysis evaluating the correlation of response and the time to response with survival and quality-adjusted outcomes. PATIENTS AND METHODS: Using a landmark approach, progression-free survival (PFS), overall survival (OS), and quality-adjusted time without symptoms or toxicity (Q-TWiST) were compared between patients with a confirmed partial or complete response at or before 6 weeks (≤ 6-week responders) and those without (≤ 6-week nonresponders)...
May 7, 2018: Clinical Lung Cancer
Marisa A Bittoni, Ashwini Arunachalam, Haojie Li, Ramon Camacho, Jinghua He, Yichen Zhong, Gregory M Lubiniecki, David P Carbone
PURPOSE: This study sought to better understand real-world treatment patterns, overall and non-small-cell lung cancer (NSCLC)-specific survival, adverse event (AE) occurrence, and economic impact of first-line cancer therapies in Medicare patients. PATIENTS AND METHODS: This retrospective cohort study identified patients ≥ 65 years in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database who received a first-time advanced (stage IV) NSCLC diagnosis from 2007 to 2011, and who received first-line platinum-based chemotherapy from 2007 through mid-2013...
May 7, 2018: Clinical Lung Cancer
Herbert H Loong, Victoria M Raymond, Yukimasa Shiotsu, Daniel T T Chua, Peter M L Teo, Tony Yung, Stan Skrzypczak, Richard B Lanman, Tony S K Mok
BACKGROUND: Genomic profiling of cell-free circulating tumor DNA (ctDNA) is a potential alternative to repeat invasive biopsy in patients with advanced cancer. We report the first real-world cohort of comprehensive genomic assessments of patients with non-small-cell lung cancer (NSCLC) in a Chinese population. PATIENTS AND METHODS: We performed a retrospective analysis of patients with advanced or metastatic NSCLC whose physician requested ctDNA-based genomic profiling using the Guardant360 platform from January 2016 to June 2017...
May 7, 2018: Clinical Lung Cancer
Shinji Atagi, Junki Mizusawa, Satoshi Ishikura, Toshiaki Takahashi, Hiroaki Okamoto, Hiroshi Tanaka, Koichi Goto, Kazuhiko Nakagawa, Masao Harada, Yuichiro Takeda, Naoyuki Nogami, Yuka Fujita, Takashi Kasai, Kazuma Kishi, Toshiyuki Sawa, Koji Takeda, Keisuke Tomii, Miyako Satouchi, Takashi Seto, Yuichiro Ohe
INTRODUCTION: In the phase III JCOG0301 trial, chemoradiotherapy (CRT) with daily low-dose carboplatin showed significant benefits in elderly patients with locally advanced non-small-cell lung cancer (NSCLC) compared with radiotherapy (RT) alone. However, the long-term patterns and cumulative incidences of toxicity associated with CRT and RT in elderly patients are not well elucidated. We report long-term survival data and late toxicities after a minimum follow-up of 6.4 years. PATIENTS AND METHODS: Eligible patients were older than 70 years and had unresectable stage III NSCLC...
May 5, 2018: Clinical Lung Cancer
Saana Andersson, Ilkka Ilonen, Tommi Järvinen, Ville Rauma, Jari Räsänen, Jarmo Salo
BACKGROUND: The role of surgery in the treatment of non-small-cell lung cancer that has spread to ipsilateral mediastinal or hilar lymph nodes (LNs) is controversial. We examined whether the location of LNs positive for non-small-cell lung cancer in mediastinum or hilum influences the survival of these patients. PATIENTS AND METHODS: We reviewed data from 881 patients and analyzed those with unsuspected N2 disease or hilar (station 10) LNs. The patients were stratified into the following groups: group A, positive hilar Naruke 10; group B, superior mediastinal and aortic nodes (Naruke 1, 2, 3, 4, 5, and 6); group C, inferior mediastinal nodes (Naruke 7, 8, and 9), and multilevel group D (2 or more positive N2 levels)...
May 5, 2018: Clinical Lung Cancer
D Ross Camidge, Lecia V Sequist, Pasi A Jänne, Andrew J Weickhardt, Elizabeth S Dowling, Jeanette Alicea, Jean Fan, Geoffrey R Oxnard
BACKGROUND: The present phase Ib study assessed the maximum tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of high-dose intermittent (HDI) afatinib monotherapy for patients with advanced solid tumors. The planned focus was patients with epidermal growth factor receptor (EGFR) T790M+ non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: Eligible patients had histologically confirmed advanced solid tumors that were unsuitable for, or unresponsive to, standard therapy...
May 5, 2018: Clinical Lung Cancer
Yusuke Okuma, Hiroshi Wakui, Hirofumi Utsumi, Yukiko Sagawa, Yukio Hosomi, Kazuyoshi Kuwano, Sadamu Homma
BACKGROUND: Biomarkers for predicting the effect of anti-programmed cell death 1 (PD-1) monoclonal antibody against non-small-cell lung cancer (NSCLC) are urgently required. Although it is known that the blood levels of soluble programmed cell death ligand 1 (sPD-L1) are elevated in various malignancies, the nature of sPD-L1 has not been thoroughly elucidated. We investigated the significance of plasma sPD-L1 levels as a biomarker for anti-PD-1 monoclonal antibody, nivolumab therapy. PATIENTS AND METHODS: The present prospective study included 39 NSCLC patients...
May 5, 2018: Clinical Lung Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"